Nektar Therapeutics
Nektar Therapeutics（NKTR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · NKTR · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
28
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Nektar Therapeutics内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
NKTR 季度内部人买卖趋势
NKTR 内幕交易卖出 · NKTR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · NKTR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
NKTR 高管卖出股份 · NKTR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 19, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 199 | $13K | Form 4 |
| May 19, 2026 | ROBIN HOWARD W President & CEO · Director | Sale | 444 | $29K | Form 4 |
| Feb 18, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 180 | $13K | Form 4 |
| Feb 18, 2026 | ROBIN HOWARD W President & CEO · Director | Sale | 423 | $31K | Form 4 |
| Jan 20, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 3,867 | $138K | Form 4 |
| Dec 22, 2025 | Zalevsky Jonathan Chief R&D Officer | Award | 6,250 | — | Form 4 |
| Dec 22, 2025 | ROBIN HOWARD W President & CEO · Director | Award | 21,667 | — | Form 4 |
| Nov 21, 2025 | Zalevsky Jonathan Chief R&D Officer | Award | 2,666 | — | Form 4 |
| Nov 25, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 1,157 | $63K | Form 4 |
| Nov 21, 2025 | Wilson Mark Andrew Chief Legal Officer | Award | 1,903 | — | Form 4 |
| Nov 25, 2025 | Wilson Mark Andrew Chief Legal Officer | Sale | 630 | $34K | Form 4 |
| Nov 21, 2025 | ROBIN HOWARD W President & CEO · Director | Award | 7,110 | — | Form 4 |
| Nov 25, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 2,207 | $120K | Form 4 |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 2,100 | $95K | Form 4 |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 1,200 | $56K | Form 4 |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 2,156 | $102K | Form 4 |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 1,210 | $58K | Form 4 |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 793 | $26K | Form 4 |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 432 | $15K | Form 4 |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 189 | $7K | Form 4 |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 307 | $11K | Form 4 |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 1,923 | $62K | Form 4 |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 1,496 | $50K | Form 4 |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 613 | $21K | Form 4 |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO · Director | Sale | 1,134 | $41K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 NKTR 内幕交易
NKTR 内幕交易
Nektar Therapeutics（NKTR）内幕交易数据来源于公司内部人（包括ROBIN HOWARD W (President & CEO · Director), Zalevsky Jonathan (Chief R&D Officer), Wilson Mark Andrew (Chief Legal Officer)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。NKTR内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Nektar Therapeutics机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
NKTR 内幕交易 · 5个问题Nektar Therapeutics（NKTR）的内部人包括高管和董事，如ROBIN HOWARD W (President & CEO · Director), Zalevsky Jonathan (Chief R&D Officer), Wilson Mark Andrew (Chief Legal Officer)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026